Mitigating Toxicity and Monitoring QOL in Chronic Myeloid Leukemia

News
Video

Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.

Jorge E. Cortes, MD, spoke with CancerNetwork® atthe 2024 American Society of Clinical Oncology (ASCO) Annual Meeting about the potential implications for quality of life and toxicity as patients with chronic myeloid leukemia (CML) undergo treatment for their disease.

Cortes, director of the Georgia Cancer Center at August University, stated that many patients have adverse effects (AEs) during therapy, although these toxicities may improve or even resolve over time. Overall, he said that most patients would be able to pursue normal activities in their day-to-day lives as they receive treatment.

Some patients, however, may experience more severe instances of toxicity such as fatigue and diarrhea. Cortes highlighted that strategies including dietary interventions or switching anti-cancer therapies may help with mitigating these AEs, thereby minimizing negative impacts on patient quality of life.

Transcript:

For most patients, they are able to continue their normal lifestyle. There is no question that there’s going to be some changes. For one, there’s some [changes] based on testing and taking [a] pill. Many patients experience some adverse [effects]. Early on, we see more of these adverse [effects]. Over time, they tend to improve; many of them do, but not always. Many of them do improve; sometimes they disappear, and sometimes they at least get better. But for most patients, they’re able to continue their activities of daily living, work, play, and family.

But there are some patients who have more limitations. The fatigue [may be] more than expected where they have chronic diarrhea, or things like that. It’s always important to know that we can sometimes manage many of these things—not all of them—by managing the [adverse] effects. If [a patient] has diarrhea, is there a dietary intervention or medication [they] can take? Other [patients] can be [treated] by changing drugs; that is the alternative. In other instances when the [toxicity] is there and even changes, how can I optimize or at least minimize the impact in [their] quality of life?

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Related Content